Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: Neurocrine is a biopharmaceutical company focused on discovering, developing, and commercializing drugs for neurological and endocrine-related diseases. The company has no approved products and generates revenue primarily through collaboration agreements, license fees, and milestone payments. Key therapeutic areas include endometriosis, anxiety, depression, insomnia, and diabetes.
Key Financial Metrics
| Metric (in thousands) | 2008 | 2007 |
|---|---|---|
| Total Revenues | $3,975 | $1,224 |
| Net Loss | $(88,613) | $(207,299) |
| Loss Per Share (Basic & Diluted) | $(2.30) | $(5.45) |
| Research & Development Expenses | $55,291 | $81,985 |
| Cash, Cash Equivalents & Short-term Investments | $80,473 | $179,385 |
| Working Capital | $55,329 | $153,041 |
| Accumulated Deficit | $(703,263) | $(614,650) |
| Long-term Debt | $0 | $0 |
Note: The company had no long-term debt as of December 31, 2008, having retired all mortgage debt in a 2007 sale-leaseback transaction.
Material Changes vs. Prior Period
- Revenue Increase: Total revenues increased 225% to $4.0 million in 2008 from $1.2 million in 2007. This was driven by $2.9 million in license fees from the Dainippon Sumitomo Pharma (DSP) agreement and a $1.0 million milestone from GlaxoSmithKline (GSK).
- Net Loss Reduction: Net loss decreased significantly to $88.6 million from $207.3 million in 2007. The 2007 loss included a one-time, non-cash asset impairment charge of $94.0 million related to a prepaid royalty for the drug candidate indiplon.
- Operating Expense Reduction: Total operating expenses dropped to $91.3 million from $213.5 million. R&D expenses decreased by $26.7 million due to staff reductions implemented in 2007. SG&A expenses decreased by $17.3 million due to similar cost-saving measures and the cessation of pre-commercialization activities for indiplon.
- Real Estate Restructuring: In Q4 2008, the company amended its facility lease, vacating the front building of its headquarters. This triggered a $15.7 million "cease-use expense" for lease termination costs but allowed for the recognition of a $3.5 million deferred gain on the 2007 real estate sale.
- Liquidity Decline: Cash and investments decreased by approximately $99 million year-over-year, primarily due to the operating loss and severance payments, despite the reduction in the impairment charge.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
- Profitability: Management does not expect to be profitable in 2009 or the foreseeable future. The company expects to continue incurring operating losses and negative cash flows.
- Liquidity: Management believes existing capital resources, investment income, and future collaboration payments will satisfy funding requirements for at least the next 12 months.
- Product Pipeline:
- Elagolix (Endometriosis): Phase IIb trials completed in 2008 showed minimal impact on bone mineral density and significant pain reduction. Phase III trials are expected to commence in early 2010.
- Indiplon (Insomnia): FDA deemed 5mg and 10mg capsules "approvable" in December 2007 but requested additional studies (elderly trial, safety comparison, pregnancy study). The company ceased U.S. clinical development and pre-commercialization activities pending FDA resolution.
- CRF Antagonists: GSK is advancing compounds for depression and anxiety into Phase II trials.
Risks and Contingencies
- Indiplon Regulatory Uncertainty: Significant uncertainty remains regarding the timeline and cost to satisfy FDA requirements for indiplon approval. Failure to meet these requirements could prevent commercialization.
- Auction Rate Securities (ARS): The company holds $22.6 million (par value) of illiquid auction rate securities. Due to market liquidity issues, these were marked down by $3.9 million to a carrying value of $18.7 million. The company may be unable to access these funds without a loss of principal until auctions succeed or securities mature.
- Collaboration Dependence: The company relies heavily on partners (GSK, DSP) for funding and development. Termination of these agreements could severely impact operations.
- Legal Proceedings: A securities class action lawsuit regarding indiplon statements was dismissed with prejudice in November 2008. A related shareholder derivative action was also dismissed.
Investor Verification Checklist
- Indiplon Status: Verify the outcome of the July 2008 FDA meeting and the feasibility/cost of the requested additional studies (elderly trial, safety comparison).
- Elagolix Phase III: Confirm the timeline for the FDA end-of-Phase II meeting (expected late 2009) and the start of Phase III trials (expected early 2010).
- Auction Rate Securities: Monitor the liquidity status of the $18.7 million ARS portfolio and the exercise period for the UBS ARS Rights (June 30, 2010 – July 2, 2012).
- Cash Burn Rate: Assess whether the $80.5 million cash balance is sufficient to fund operations through 2010 given the continued negative operating cash flow.
- Lease Obligations: Review the impact of the amended facility lease, including the $15.7 million cease-use liability and future rent reduction potential from subleasing the vacated front building.